Label Expansion for Oral Ibrutinib Suspension Gets FDA Approval
February 29th 2024The label expansion for ibrutinib with an oral suspension formulation has been approved by the FDA in all current indications including Waldenström macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, and chronic graft-versus-host disease.
Bi-weekly Teclistamab Dosing Receives FDA Approval for Relapsed/Refractory Multiple Myeloma
February 21st 2024A supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) has been approved by the FDA at a reduced dose of 1.5 mg/kg every 2 weeks for the treatment of patients with relapsed/refractory multiple myeloma who have maintained a complete response or greater for at least 6 months.
SBRT Plus Standard of Care Improves PFS in Oligoprogressive NSCLC
February 19th 2024Stereotactic ablative radiotherapy with standard-of-care therapy improved progression-free survival in patients with oligoprogressive non-small cell lung cancer, although the benefit was not seen in those with oligoprogressive breast cancer.
Tislelizumab Plus Chemo Improves Event-Free Survival in Stage II-IIIA NSCLC
February 17th 2024The use of perioperative tislelizumab plus neoadjuvant chemotherapy has been supported by findings from the phase 3 RATIONALE-315 study as a treatment for resectable stage II to IIIA non–small cell lung cancer.
Osimertinib Receives Approval From FDA for EGFR-Mutated Locally Advanced or Metastatic NSCLC
February 16th 2024The FDA approved osimertinib for use with platinum-based chemotherapy to treat patients with locally advanced or metastatic non-small cell lung cancer that harbor EGFR exon 19 deletions or exon 21 L858R mutations.